More on NUVB
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $6.42 |
|
|||
| Open | $6.42 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $6.42 | ||||
| Day Low | $6.42 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 525 | ||||
- Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
- RBC Capital on Nuvation Bio Inc (NUVB): 'Ibtrozi Growth, Safu Optionality Create A Compelling Setup'
- Nuvation Bio expands safusidenib trials after Phase 2 data update
- Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
- Form 4 Nuvation Bio Inc. For: Jul 15 Filed by: Sauvage Philippe
- Nuvation Bio Inc (NUVB) PT Lowered to $19 at RBC Capital
- Nuvation Bio Inc (NUVB) PT Raised to $13 at Truist Securities
- Form 8-K Nuvation Bio Inc. For: Jun 30
- Nuvation Bio raises $277.6M net in convertible notes after greenshoe
- Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
Entities mentioned with NUVB
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Earnings | View Related Stories »
- S1 | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
